<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Natl Cancer Inst</journal-id><journal-id journal-id-type="iso-abbrev">J Natl Cancer Inst</journal-id><journal-id journal-id-type="pmc-domain-id">753</journal-id><journal-id journal-id-type="pmc-domain">jnci</journal-id><journal-id journal-id-type="publisher-id">jnci</journal-id><journal-title-group><journal-title>JNCI Journal of the National Cancer Institute</journal-title></journal-title-group><issn pub-type="ppub">0027-8874</issn><issn pub-type="epub">1460-2105</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9905963</article-id><article-id pub-id-type="pmcid-ver">PMC9905963.1</article-id><article-id pub-id-type="pmcaid">9905963</article-id><article-id pub-id-type="pmcaiid">9905963</article-id><article-id pub-id-type="pmid">36315097</article-id><article-id pub-id-type="doi">10.1093/jnci/djac196</article-id><article-id pub-id-type="publisher-id">djac196</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><subj-group subj-group-type="category-oup-series"><subject>Editor's Choice</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00010</subject></subj-group></article-categories><title-group><article-title>Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4739-1526</contrib-id><name name-style="western"><surname>Lim</surname><given-names initials="BWX">Belle W X</given-names></name><degrees>PhD</degrees><aff>
<institution>Cancer Genetics Laboratory, Peter MacCallum Cancer Centre</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff><aff>
<institution>Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff><xref rid="djac196-FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1578-9561</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="N">Na</given-names></name><degrees>PhD</degrees><aff>
<institution>Cancer Genetics Laboratory, Peter MacCallum Cancer Centre</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff><aff>
<institution>Sir Peter MacCallum Department of Oncology, The University of Melbourne</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff><aff>
<institution>Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre&#160;and&#160;Royal Melbourne Hospital</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mahale</surname><given-names initials="S">Sakshi</given-names></name><degrees>MSc</degrees><aff>
<institution>Cancer Genetics Laboratory, Peter MacCallum Cancer Centre</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>McInerny</surname><given-names initials="S">Simone</given-names></name><degrees>BSc</degrees><aff>
<institution>Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre&#160;and&#160;Royal Melbourne Hospital</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6528-891X</contrib-id><name name-style="western"><surname>Zethoven</surname><given-names initials="M">Magnus</given-names></name><degrees>MSc</degrees><aff>
<institution>Cancer Genetics Laboratory, Peter MacCallum Cancer Centre</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff><aff>
<institution>Bioinformatics Core Facility, Peter MacCallum Cancer Centre</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rowley</surname><given-names initials="SM">Simone M</given-names></name><degrees>BSc</degrees><aff>
<institution>Cancer Genetics Laboratory, Peter MacCallum Cancer Centre</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huynh</surname><given-names initials="J">Joanne</given-names></name><degrees>BSc</degrees><aff>
<institution>Cancer Genetics Laboratory, Peter MacCallum Cancer Centre</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="T">Theresa</given-names></name><degrees>BSc</degrees><aff>
<institution>Cancer Genetics Laboratory, Peter MacCallum Cancer Centre</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff><aff>
<institution>Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre&#160;and&#160;Royal Melbourne Hospital</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="JEA">Jue Er Amanda</given-names></name><degrees>PhD</degrees><aff>
<institution>Cancer Genetics Laboratory, Peter MacCallum Cancer Centre</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff><aff>
<institution>Sir Peter MacCallum Department of Oncology, The University of Melbourne</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff><aff>
<institution>Molecular Genomics Core, Peter MacCallum Cancer Centre</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Friedman</surname><given-names initials="M">Mia</given-names></name><degrees>BSc</degrees><aff>
<institution>Cancer Genetics Laboratory, Peter MacCallum Cancer Centre</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff><aff>
<institution>Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre&#160;and&#160;Royal Melbourne Hospital</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Devereux</surname><given-names initials="L">Lisa</given-names></name><degrees>MSc</degrees><aff>
<institution>Sir Peter MacCallum Department of Oncology, The University of Melbourne</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff><aff>
<institution>Lifepool, Peter MacCallum Cancer Centre</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Scott</surname><given-names initials="RJ">Rodney J</given-names></name><degrees>PhD</degrees><aff>
<institution>Discipline of Medical Genetics and The Centre for Cancer Detection and Therapy, The University of Newcastle and Hunter Medical Research Institute</institution>, Newcastle, New South Wales, <country country="AU">Australia</country></aff><aff>
<institution>Division of Molecular Medicine, New South Wales Health Pathology North</institution>, Newcastle, New South Wales, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sloan</surname><given-names initials="EK">Erica K</given-names></name><degrees>PhD</degrees><aff>
<institution>Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff><aff>
<institution>Division of Cancer Surgery, Peter MacCallum Cancer Centre</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>James</surname><given-names initials="PA">Paul A</given-names></name><degrees>PhD</degrees><aff>
<institution>Sir Peter MacCallum Department of Oncology, The University of Melbourne</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff><aff>
<institution>Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre&#160;and&#160;Royal Melbourne Hospital</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff><xref rid="djac196-FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7773-4155</contrib-id><name name-style="western"><surname>Campbell</surname><given-names initials="IG">Ian G</given-names></name><degrees>PhD</degrees><aff>
<institution>Cancer Genetics Laboratory, Peter MacCallum Cancer Centre</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff><aff>
<institution>Sir Peter MacCallum Department of Oncology, The University of Melbourne</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff><aff>
<institution>Lifepool, Peter MacCallum Cancer Centre</institution>, Melbourne, Victoria, <country country="AU">Australia</country></aff><xref rid="djac196-cor1" ref-type="corresp"/><xref rid="djac196-FM1" ref-type="author-notes"/></contrib></contrib-group><author-notes><corresp id="djac196-cor1"><bold>Correspondence to:</bold> Ian Campbell, PhD, Cancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC 3000, Australia (e-mail: <email>ian.campbell@petermac.org</email>).</corresp><fn id="djac196-FM1"><p>Belle W. X. Lim, Paul A. James and Ian G. Campbell contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><month>2</month><year>2023</year></pub-date><pub-date pub-type="epub" iso-8601-date="2022-10-31"><day>31</day><month>10</month><year>2022</year></pub-date><volume>115</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">428500</issue-id><fpage>181</fpage><lpage>189</lpage><history><date date-type="received"><day>13</day><month>2</month><year>2022</year></date><date date-type="rev-recd"><day>17</day><month>6</month><year>2022</year></date><date date-type="accepted"><day>18</day><month>10</month><year>2022</year></date><date date-type="corrected-typeset"><day>14</day><month>12</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>10</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>09</day><month>02</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-02-10 00:10:59.230"><day>10</day><month>02</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2022. Published by Oxford University Press.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="djac196.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="djac196.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Breast cancers (BCs) that arise in individuals heterozygous for a germline pathogenic variant in a susceptibility gene, such as <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">PALB2</italic>, and <italic toggle="yes">RAD51C</italic>, have been shown to exhibit biallelic loss in the respective genes and be associated with triple-negative breast cancer (TNBC) and distinctive somatic mutational signatures. Tumor sequencing thus presents an orthogonal approach to assess the role of candidate genes in BC development.</p></sec><sec id="s2"><title>Methods</title><p>Exome sequencing was performed on paired normal-breast tumor DNA from 124 carriers of germline loss-of-function (LoF) or missense variant carriers in 15 known and candidate BC predisposition genes identified in the BEACCON case-control study. Biallelic inactivation and association with tumor genome features including mutational signatures and homologous recombination deficiency (HRD) score were investigated.</p></sec><sec id="s3"><title>Results</title><p>
<italic toggle="yes">BARD1</italic>-carrying TNBC (4 of 5) displayed biallelic loss and associated high HRD scores and mutational signature 3, as did a <italic toggle="yes">RAD51D</italic>-carrying TNBC and ovarian cancer. Biallelic loss was less frequent in <italic toggle="yes">BRIP1</italic> BCs (4 of 13) and had low HRD scores. In contrast to other established BC genes, BCs from carriers of <italic toggle="yes">CHEK2</italic> LoF (6 of 17) or missense (2 of 20) variant had low rates of biallelic loss. Exploratory analysis of BC from carriers of LoF variants in candidate genes such as <italic toggle="yes">BLM</italic>, <italic toggle="yes">FANCM</italic>, <italic toggle="yes">PARP2</italic>, and <italic toggle="yes">RAD50</italic> found little evidence of biallelic inactivation.</p></sec><sec id="s4"><title>Conclusions</title><p>
<italic toggle="yes">BARD1</italic> and <italic toggle="yes">RAD51D</italic> behave as classic BRCA-like predisposition genes with biallelic inactivation, but this was not observed for any of the candidate genes. However, as demonstrated for <italic toggle="yes">CHEK2</italic>, the absence of biallelic inactivation does not provide definitive evidence against the gene&#8217;s involvement in BC predisposition.</p></sec></abstract><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Breast Cancer Foundation</institution><institution-id institution-id-type="DOI">10.13039/501100001026</institution-id></institution-wrap></funding-source><award-id>IF-15-004</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Breast Cancer Foundation</institution><institution-id institution-id-type="DOI">10.13039/501100001026</institution-id></institution-wrap></funding-source><award-id>PdCCRS_1107870</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Breast Cancer Foundation</institution><institution-id institution-id-type="DOI">10.13039/501100001026</institution-id></institution-wrap></funding-source><award-id>PdCCRS_1188547</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Victorian Cancer Agency</institution><institution-id institution-id-type="DOI">10.13039/100008018</institution-id></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Health and Medical Research Council of Australia</institution></institution-wrap></funding-source><award-id>GNT1023698</award-id><award-id>GNT1041975</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Cancer Australia</institution><institution-id institution-id-type="DOI">10.13039/501100001111</institution-id></institution-wrap></funding-source><award-id>PdCCRS_1188547</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Health and Medical Research Council</institution><institution-id institution-id-type="DOI">10.13039/501100000925</institution-id></institution-wrap></funding-source><award-id>GNT114749</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Breast Cancer Foundation</institution><institution-id institution-id-type="DOI">10.13039/501100001026</institution-id></institution-wrap></funding-source><award-id>IIRS-20-025</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Cancer Council Victoria Grants-in-Aid</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Cancer Council Victoria</institution><institution-id institution-id-type="DOI">10.13039/501100000951</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><page-count count="9"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Hereditary breast cancer (HBC) often clusters within families and can be attributed to germline variants in susceptibility genes directly or indirectly involved in DNA repair. The major contributors&#8212;<italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, and <italic toggle="yes">PALB2</italic> (<xref rid="djac196-B1" ref-type="bibr">1</xref>,<xref rid="djac196-B2" ref-type="bibr">2</xref>)&#8212;collectively explain less than half of the familial aggregation of BC (<xref rid="djac196-B3" ref-type="bibr">3</xref>). Exploratory case-control studies in the past have found that potentially pathogenic variants in individual candidate genes are rare (<xref rid="djac196-B3" ref-type="bibr">3-5</xref>), precluding any confident conclusion about their role in HBC based solely on this approach.</p><p>An orthogonal approach to assess if a candidate gene is driving tumorigenesis is through genomic analysis of the cancers from carriers of germline mutations. For example, approximately 90% of <italic toggle="yes">BRCA1</italic> and 50%-60% of <italic toggle="yes">BRCA2</italic> breast tumors from germline mutation carriers have a somatic &#8220;second-hit&#8221; (<xref rid="djac196-B6" ref-type="bibr">6-9</xref>), resulting in biallelic inactivation. Most commonly, this occurs through loss of heterozygosity (LOH) or, less frequently, through protein truncating somatic point mutations or promoter hypermethylation. Biallelic inactivation of genes such as <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> is almost invariably associated with specific somatic mutational signatures (<xref rid="djac196-B10" ref-type="bibr">10</xref>). The presence or absence of these tumor genomic features can provide strong evidence for or against a gene&#8217;s cancer predisposition role, even if based on relatively few cancers as previously demonstrated for <italic toggle="yes">PALB2</italic>, <italic toggle="yes">RAD51C</italic>, and <italic toggle="yes">ATM</italic> (<xref rid="djac196-B11" ref-type="bibr">11-13</xref>). Recent large case-control studies involving more than 65&#8202;000 participants each confirmed the association of moderate risk genes <italic toggle="yes">RAD51C</italic>, <italic toggle="yes">RAD51D</italic>, and <italic toggle="yes">BARD1</italic> but not <italic toggle="yes">BRIP1</italic> with breast cancer (<xref rid="djac196-B4" ref-type="bibr">4</xref>,<xref rid="djac196-B5" ref-type="bibr">5</xref>).</p><p>In this study, we extend the tumor sequencing approach by performing exome sequencing on 124 BCs from individuals harboring germline variants in proposed and candidate HBC genes identified in the BEACCON case-control study (hereditary BrEAst Case CONtrol study) (<xref rid="djac196-B3" ref-type="bibr">3</xref>) to look for evidence of biallelic inactivation as a means of validating the role of these genes in BC predisposition.</p><sec sec-type="methods"><title>Methods</title><sec><title>Case-control study and tumor sequencing</title><p>A total of 124 unique breast tumors were selected from cancers arising in individuals with a germline loss-of-function (LoF) or rare, likely pathogenic missense (MS) variant of interest in a known (<italic toggle="yes">BARD1</italic>, <italic toggle="yes">BRIP1</italic>, <italic toggle="yes">CHEK2</italic>, and <italic toggle="yes">RAD51D)</italic> or candidate (<italic toggle="yes">BLM</italic>, <italic toggle="yes">CDK9</italic>, <italic toggle="yes">CTH</italic>, <italic toggle="yes">ERCC5</italic>, <italic toggle="yes">FANCM</italic>, <italic toggle="yes">MUTYH</italic>, <italic toggle="yes">PARP2</italic>, <italic toggle="yes">RAD50</italic>, <italic toggle="yes">RAD51B</italic>, <italic toggle="yes">WRN</italic>, and <italic toggle="yes">XRCC2</italic>) BC predisposition gene detected in the BEACCON case-control study (<xref rid="djac196-B3" ref-type="bibr">3</xref>). LoF variants included stop-gained, frame-shift, or essential splice-site variants, and MS variants of interest were identified based on a combination of population frequency, in silico prediction, and location in key functional domains as detailed in <xref rid="sup1" ref-type="supplementary-material">Supplementary Tables 1-4</xref> (available online). Two ovarian cancers from carriers of <italic toggle="yes">BRIP1</italic> and 1 of <italic toggle="yes">RAD51D</italic> LoF variants, respectively, were also included as these genes are known to be ovarian cancer predisposing genes. Since last reporting (<xref rid="djac196-B5" ref-type="bibr">5</xref>), this study has been expanded to include 6689 BRCA-negative female index familial BC patients and 14&#8202;381 cancer-free female participants (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 5</xref>, available online). Candidate genes were selected for this analysis based on an excess of rare coding variants in the case group. Microdissection, DNA extraction, and exome sequencing are described in the <xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref> (available online). Tumor characteristics and personal and family history of the individuals selected for the current study are summarized in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 6</xref> (available online).</p></sec><sec><title>Determination of variant allelic status and potential biallelic inactivation</title><p>For each tumor, the somatic sequencing data were assessed for the presence of somatic LoF or MS point mutations in the gene of interest as well as the allelic status of the germline variant as described previously (<xref rid="djac196-B11" ref-type="bibr">11</xref>,<xref rid="djac196-B12" ref-type="bibr">12</xref>). In summary, locus-specific LOH was determined by tumor variant allele frequency comparisons as adjusted according to estimated tumor purity. All cases had matched germline sequencing data for the gene of interest. Promoter hypermethylation, using targeted Twist Custom Panel methylation sequencing or Sanger sequencing on bisulfite converted DNA, was also assessed for cases where there was no somatic mutation or LOH across the gene of interest. Homologous recombination deficiency (HRD) scores were calculated for each tumor sample using copy number plots as a sum of the occurrence of telomeric allelic imbalances, large-scale state transitions, and homologous recombination deficiency&#8211;loss of heterozygosity from copy number plots as described previously (<xref rid="djac196-B12" ref-type="bibr">12</xref>), where a threshold of an HRD score of 42 or higher is defined as high-HRD (<xref rid="djac196-B14" ref-type="bibr">14</xref>,<xref rid="djac196-B15" ref-type="bibr">15</xref>). Mutational signatures were generated against COSMIC v2 catalogue (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cancer.sanger.ac.uk/signatures/signatures_v2/" ext-link-type="uri">https://cancer.sanger.ac.uk/signatures/signatures_v2/</ext-link>) using the DeconstructSig package in R (<xref rid="djac196-B16" ref-type="bibr">16</xref>) on whole-exome sequenced samples.</p></sec><sec><title>Statistical analyses</title><p>Odds ratios and Fisher exact test (2-sided) were calculated in case-control analyses, with a 2-tailed <italic toggle="yes">P</italic> value of .05 or less defined as statistically significant. Confidence intervals (CIs) were calculated using a conditional maximum likelihood estimate. All calculations were carried out using R-in built function in R 3.3.2 (<xref rid="djac196-B17" ref-type="bibr">17</xref>).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Tumor sequencing in individuals harboring a germline variant in known BC genes</title><p>Whole or targeted exome sequencing was performed on 41 tumors from individuals harboring germline LoF variants in genes commonly present in HBC panels: <italic toggle="yes">BARD1</italic> (n&#8201;=&#8201;7), <italic toggle="yes">BRIP1</italic> (n&#8201;=&#8201;13), <italic toggle="yes">RAD51D</italic> (n&#8201;=&#8201;4), and <italic toggle="yes">CHEK2</italic> (n&#8201;=&#8201;17) (<xref rid="djac196-T1" ref-type="table">Table&#160;1</xref>). <italic toggle="yes">BARD1</italic>, which in the BEACCON case-control data (<xref rid="djac196-F1" ref-type="fig">Figure&#160;1</xref>) and other published data (<xref rid="djac196-B4" ref-type="bibr">4</xref>) is associated specifically with triple-negative breast cancer (TNBC), showed loss of the wild-type (WT) allele via LOH in 4 of 5 assessable triple negative (TN) tumors. A sixth TN tumor also had LOH, but it was not possible to determine which allele had been lost, and the only <italic toggle="yes">BARD1</italic> tumor to show loss of the mutant allele was estrogen receptor (ER) positive. The 6 <italic toggle="yes">BARD1</italic> TN tumors including 1 in heterozygous status showed high HRD scores and 4 with strong HRD-related mutational signature 3. Carriers of <italic toggle="yes">RAD51D</italic> LoF mutations, which are also associated with TNBC, were rare in the BEACCON study. One of the 2 TNBC showed LOH of the WT allele, whereas 2 ER-positive tumors remained heterozygous. An additional high-grade serous ovarian cancer (HGSOC) that was available for analysis (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 5</xref>, available online) showed biallelic inactivation through LOH. Nine carriers of rare <italic toggle="yes">RAD51D</italic> MS variants shortlisted based on likely pathogenicity assessment (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>, available online) were also analyzed, but only 2 cases showed loss of the WT allele with only 1 of these being a TNBC. This case was a compound heterozygote that showed loss of the p.Ala313Val and retention of the p.Ala52Val allele; it had a high HRD score and a strong mutational signature 3.</p><fig position="float" id="djac196-F1" orientation="portrait"><label>Figure 1.</label><caption><p>Case-control analysis of rare LoF variants (minor allele frequency [MAF]&#8201;&#8804;&#8201;0.005) and MS variants (MAF &#8804; 0.001) in known or strongly proposed breast cancer genes, including subcategories of estrogen receptor&#8211;positive (ER+), ER-negative (ER-), and triple-negative (TN) breast tumor where diagnosis was available. ER+ and ER- groups were mutually exclusive, and the ER- groups include the TN samples. Participants without sufficient pathological information were only included in the overall LoF group and excluded from the subcategory analysis. <italic toggle="yes">CHEK2</italic>, <italic toggle="yes">BARD1</italic>, and <italic toggle="yes">BRIP1</italic> were screened in 6689 cases and 14&#8202;381 controls; <italic toggle="yes">RAD51C</italic> and <italic toggle="yes">RAD51D</italic> were screened in 5726 cases and 13&#8202;428 controls. The sample sizes of ER+, ER-, and TN were 2146, 1246, and 862, respectively. CI = confidence interval; LoF = loss of function; MS = missense; OR = odds ratio (<xref rid="djac196-B3" ref-type="bibr">3</xref>,<xref rid="djac196-B4" ref-type="bibr">4</xref>,<xref rid="djac196-B11" ref-type="bibr">11</xref>,<xref rid="djac196-B12" ref-type="bibr">12</xref>,<xref rid="djac196-B18" ref-type="bibr">18</xref>,<xref rid="djac196-B19" ref-type="bibr">19</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="djac196f1.jpg"/></fig><table-wrap position="float" id="djac196-T1" orientation="portrait"><label>Table 1.</label><caption><p>Tumor sequencing data for 69 tumors from individuals heterozygous for a germline LoF (n&#8201;=&#8201;41) or MS (n&#8201;=&#8201;29) variant in a known breast cancer predisposition gene (<italic toggle="yes">BARD1</italic>, <italic toggle="yes">BRIP1</italic>, <italic toggle="yes">CHEK2</italic>, and <italic toggle="yes">RAD51D</italic>)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">ID<xref rid="tblfn1" ref-type="table-fn"><sup>a</sup></xref></th><th rowspan="1" colspan="1">Gene</th><th rowspan="1" colspan="1">Germline variant</th><th rowspan="1" colspan="1">Variant type</th><th rowspan="1" colspan="1">Variant allelic status<xref rid="tblfn2" ref-type="table-fn"><sup>b</sup></xref></th><th rowspan="1" colspan="1">BC subtype</th><th rowspan="1" colspan="1">HRD</th><th rowspan="1" colspan="1">Somatic <italic toggle="yes">TP53</italic></th><th rowspan="1" colspan="1">Somatic <italic toggle="yes">PIK3CA</italic></th><th rowspan="1" colspan="1">Mutation signature 3<xref rid="tblfn3" ref-type="table-fn"><sup>c</sup></xref></th><th rowspan="1" colspan="1">Dominant mutation signature</th><th rowspan="1" colspan="1">Promoter hypermethylation</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">3530</td><td rowspan="1" colspan="1">
<italic toggle="yes">BARD1</italic>
</td><td rowspan="1" colspan="1">c.1135A&gt;T,&#160;p.Lys379Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Mutant loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">3977</td><td rowspan="1" colspan="1">
<italic toggle="yes">BARD1</italic>
</td><td rowspan="1" colspan="1">c.1212C&gt;G,&#160;p.Tyr404Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">3, 11</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">1531</td><td rowspan="1" colspan="1">
<italic toggle="yes">BARD1</italic>
</td><td rowspan="1" colspan="1">c.1652C&gt;G,&#160;p.Ser551Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">83</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">19, 30</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">3828</td><td rowspan="1" colspan="1">
<italic toggle="yes">BARD1</italic>
</td><td rowspan="1" colspan="1">c.1652C&gt;G,&#160;p.Ser551Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">92</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">1, 3</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">425</td><td rowspan="1" colspan="1">
<italic toggle="yes">BARD1</italic>
</td><td rowspan="1" colspan="1">c.1652C&gt;G,&#160;p.Ser551Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">LOH</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">3496</td><td rowspan="1" colspan="1">
<italic toggle="yes">BARD1</italic>
</td><td rowspan="1" colspan="1">c.1905G&gt;A,&#160;p.Trp635Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">82</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">1272</td><td rowspan="1" colspan="1">
<italic toggle="yes">BARD1</italic>
</td><td rowspan="1" colspan="1">c.2078_2079insTAATA,&#160;p.Lys693AsnfsTer23</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">2439</td><td rowspan="1" colspan="1">
<italic toggle="yes">BRIP1</italic>
</td><td rowspan="1" colspan="1">c.93&#8201;+&#8201;1G&gt;T</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">3, 19</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">4160</td><td rowspan="1" colspan="1">
<italic toggle="yes">BRIP1</italic>
</td><td rowspan="1" colspan="1">c.103G&gt;T,&#160;p.Gly35Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Mutant loss</td><td rowspan="1" colspan="1">ER-/HER2+</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">1, 3</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">3259</td><td rowspan="1" colspan="1">
<italic toggle="yes">BRIP1</italic>
</td><td rowspan="1" colspan="1">c.1426del,&#160;p.Thr476LeufsTer50</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">12, 20</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">3597</td><td rowspan="1" colspan="1">
<italic toggle="yes">BRIP1</italic>
</td><td rowspan="1" colspan="1">c.1888dup,&#160;p.Thr630AsnfsTer9</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">3093</td><td rowspan="1" colspan="1">
<italic toggle="yes">BRIP1</italic>
</td><td rowspan="1" colspan="1">c.2298_2301delTGAG,&#160;p.Ser766ArgfsTer14</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">227</td><td rowspan="1" colspan="1">
<italic toggle="yes">BRIP1</italic>
</td><td rowspan="1" colspan="1">c.2392C&gt;T,&#160;p.Arg798Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">58</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">20, 21</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">1325</td><td rowspan="1" colspan="1">
<italic toggle="yes">BRIP1</italic>
</td><td rowspan="1" colspan="1">c.2392C&gt;T,&#160;p.Arg798Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Mutant loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">57</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">786</td><td rowspan="1" colspan="1">
<italic toggle="yes">BRIP1</italic>
</td><td rowspan="1" colspan="1">c.2392C&gt;T,&#160;p.Arg798Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">1928</td><td rowspan="1" colspan="1">
<italic toggle="yes">BRIP1</italic>
</td><td rowspan="1" colspan="1">c.2392C&gt;T,&#160;p.Arg798Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">3829</td><td rowspan="1" colspan="1">
<italic toggle="yes">BRIP1</italic>
</td><td rowspan="1" colspan="1">c.2400C&gt;G,&#160;p.Tyr800Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Mutant loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">3635</td><td rowspan="1" colspan="1">
<italic toggle="yes">BRIP1</italic>
</td><td rowspan="1" colspan="1">c.2400C&gt;G,&#160;p.Tyr800Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">3354</td><td rowspan="1" colspan="1">
<italic toggle="yes">BRIP1</italic>
</td><td rowspan="1" colspan="1">c.2492_2492&#8201;+&#8201;5delGGTAAG</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">3468</td><td rowspan="1" colspan="1">
<italic toggle="yes">BRIP1</italic>
</td><td rowspan="1" colspan="1">c.3715del,&#160;p.Ser1239ProfsTer15</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Mutant loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">1, 13</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">4152</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.629_732delCAGT,&#160;p.Ser210PhefsTer6</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Mutant loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">2320</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.630delA,&#160;p.Val211PhefsTer6</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">5, 30</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">290</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.902delT,&#160;p.Leu301TrpfsTer3</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Mutant loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">1,6</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">3587</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1100delC,&#160;p.Thr367MetfsTer15</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">34</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">1825</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1100delC,&#160;p.Thr367MetfsTer15</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">3174</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1100delC,&#160;p.Thr367MetfsTer15</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">6, 30</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">2182</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1100delC,&#160;p.Thr367MetfsTer15</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">11, 19</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">2410</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1100delC,&#160;p.Thr367MetfsTer15</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">1, 30</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">2475</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1100delC,&#160;p.Thr367MetfsTer15</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">6, 19</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">1300</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1100delC,&#160;p.Thr367MetfsTer15</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">2326</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1100delC,&#160;p.Thr367MetfsTer15</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">19, 30</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">2711</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1100delC,&#160;p.Thr367MetfsTer15</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT loss</td><td rowspan="1" colspan="1">ER+/HER2+</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">1, 11</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">3500</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1100delC,&#160;p.Thr367MetfsTer15</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2unknown</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">2351</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1100delC,&#160;p.Thr367MetfsTer15</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER-/HER2+</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">19, 30</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">3076</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1100delC,&#160;p.Thr367MetfsTer15</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER-/HER2+</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">1732</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1100delC,&#160;p.Thr367MetfsTer15</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT Loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">1853</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1696delC,&#160;p.Thr533GlnfsTer33</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">2625</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.14C&gt;T,&#160;p.Ser5Leu</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">85</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">1993</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.190G&gt;A,&#160;p.Glu64Lys</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">91</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">1, 6</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">811</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.349A&gt;G,&#160;p.Arg117Gly</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2+</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">1103</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.349A&gt;G,&#160;p.Arg117Gly</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Mutant loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">616</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.349A&gt;G,&#160;p.Arg117Gly</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER-/HER2+</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">1, 3</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">787</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.442A&gt;G,&#160;p.Arg148Gly</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">2531</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.470T&gt;C,&#160;p.Ile157Thr</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">34</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">1420</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.470T&gt;C,&#160;p.Ile157Thr</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">3240</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.470T&gt;C,&#160;p.Ile157Thr</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">3, 6</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">807</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1036C&gt;T,&#160;p.Arg346Cys; c.499G&gt;A, p. Gly167Arg</td><td rowspan="1" colspan="1">MS<break/>MS</td><td rowspan="1" colspan="1">WT loss; mutant loss</td><td rowspan="1" colspan="1">ER+/HER2unknown</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">2091</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1067C&gt;T,&#160;p.Ser356Leu</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">1, 19</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">2689</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1211A&gt;G,&#160;p.Tyr404Cys</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">WT loss</td><td rowspan="1" colspan="1">ER+/HER2+</td><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">3, 30</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">2221</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1270T&gt;C,&#160;p.Tyr424His</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">WT loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">1830</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1312G&gt;T,&#160;p.Asp438Tyr</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">2257</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1312G&gt;T,&#160;p.Asp438Tyr</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">200</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1312G&gt;T,&#160;p.Asp438Tyr</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">4164</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1427C&gt;T,&#160;p.Thr476Met</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">11, 19</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">1410</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1447C&gt;T,&#160;p.His483Tyr</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Mutant loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">2345</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1525C&gt;T,&#160;p.Pro509Ser</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Mutant loss</td><td rowspan="1" colspan="1">ER+/HER2+</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">1198</td><td rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td><td rowspan="1" colspan="1">c.1604G&gt;A,&#160;p.Arg535His</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">6, 30</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">1897</td><td rowspan="1" colspan="1">
<italic toggle="yes">RAD51D</italic>
</td><td rowspan="1" colspan="1">c.616C&gt;T,&#160;p.Arg206Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">2734</td><td rowspan="1" colspan="1">
<italic toggle="yes">RAD51D</italic>
</td><td rowspan="1" colspan="1">c.754C&gt;T,&#160;p.Arg252Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">2866</td><td rowspan="1" colspan="1">
<italic toggle="yes">RAD51D</italic>
</td><td rowspan="1" colspan="1">c.808delC,&#160;p.His270ThrfsTer2</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">3500</td><td rowspan="1" colspan="1">
<italic toggle="yes">RAD51D</italic>
</td><td rowspan="1" colspan="1">c.863G&gt;A,&#160;p.Trp288Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">506</td><td rowspan="1" colspan="1">
<italic toggle="yes">RAD51D</italic>
</td><td rowspan="1" colspan="1">c.26G&gt;C,&#160;p.Cys9Ser</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">
<italic toggle="yes">RAD51D</italic>
</td><td rowspan="1" colspan="1">c.26G&gt;C,&#160;p.Cys9Ser</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">2936</td><td rowspan="1" colspan="1">
<italic toggle="yes">RAD51D</italic>
</td><td rowspan="1" colspan="1">c.26G&gt;C,&#160;p.Cys9Ser</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">1980</td><td rowspan="1" colspan="1">
<italic toggle="yes">RAD51D</italic>
</td><td rowspan="1" colspan="1">c.26G&gt;C,&#160;p.Cys9Ser</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">2224</td><td rowspan="1" colspan="1">
<italic toggle="yes">RAD51D</italic>
</td><td rowspan="1" colspan="1">c.137C&gt;G,&#160;p.Ser46Cys</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">2219</td><td rowspan="1" colspan="1">
<italic toggle="yes">RAD51D</italic>
</td><td rowspan="1" colspan="1">c.155C&gt;T,&#160;p.Ala52Val; c.938C&gt;T, p. Ala313Val</td><td rowspan="1" colspan="1">MS compound homozygous</td><td rowspan="1" colspan="1">WT loss; mutant loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">1686</td><td rowspan="1" colspan="1">
<italic toggle="yes">RAD51D</italic>
</td><td rowspan="1" colspan="1">c.308C&gt;T,&#160;p.Ala103Val</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">3095</td><td rowspan="1" colspan="1">
<italic toggle="yes">RAD51D</italic>
</td><td rowspan="1" colspan="1">c.472A&gt;C,&#160;p.Asn158His</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Mutant Loss</td><td rowspan="1" colspan="1">ER+/HER2+</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">2606</td><td rowspan="1" colspan="1">
<italic toggle="yes">RAD51D</italic>
</td><td rowspan="1" colspan="1">c.551T&gt;C,&#160;p.Leu184Pro</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">WT Loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">DNT</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>a</label><p>Subject 3093 carried 2 variants of interest in <italic toggle="yes">BRIP1</italic>; subject 2219 carried 2 variants in <italic toggle="yes">RAD51C</italic>; subject 3500 carried a variant of interest in both <italic toggle="yes">CHEK2</italic> and <italic toggle="yes">RAD51D</italic>. &#8220;&#8212;&#8221; signifies feature not present. BC = breast cancer; DNT = did not test; na = not available; ER+ = estrogen receptor&#8212;positive breast cancer; HER2- = HER2 negative; HER2+ = HER2 positive; HRD = homologous recombination deficiency score; LoF = loss of function; MS = missense; TN = triple-negative; WT = wild type.</p></fn><fn id="tblfn2"><label>b</label><p>WT loss, somatic loss of the WT allele; mutant loss, somatic loss of the allele carrying the known germline variant; Het, heterozygous. Case 425 showed loss of heterozygosity across the gene regions but unable to determine which allele had been lost.</p></fn><fn id="tblfn3"><label>c</label><p>Proportion of mutational signature 3 (COSMIC v2, assessed on whole-exome sequenced tumors only) above 25% is classified as &#8220;strong&#8221;, under 25% as &#8220;weak&#8221;.</p></fn></table-wrap-foot></table-wrap><p>The role of <italic toggle="yes">BRIP1</italic> in breast cancer predisposition is debated, and our analysis of <italic toggle="yes">BRIP1</italic> LoF variants identified an equal number of tumors showing loss of the WT or mutant alleles (4 cases each) with the remaining 5 remaining heterozygous. By comparison, analysis of 2 HGSOCs showed both had loss of the WT (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 5</xref>, available online), consistent with the established role of <italic toggle="yes">BRIP1</italic> in ovarian cancer predisposition. Both HGSOCs also showed high HRD scores compared with only 2 of 4 <italic toggle="yes">BRIP1-</italic>null BCs. Mutational signature 3 was observed only in 1 <italic toggle="yes">BRIP1</italic>-null BC and not in the HGSOCs.</p><p>LoF mutations in <italic toggle="yes">CHEK2</italic>, predominantly the c.1100delC variant, are well established to confer a two- to threefold increase in BC risk (<xref rid="djac196-B20" ref-type="bibr">20</xref>), with the association being strongest for ER-positive BC. The current tumor data do not provide evidence that <italic toggle="yes">CHEK2</italic> requires biallelic inactivation with the majority (9 of 17) of tumors remaining heterozygous, whereas only 6 showed loss of the WT allele, and 2 ER-positive tumors showed loss of the LoF allele. It appears that the 2 tumors with loss of pathogenic variants were not driven by <italic toggle="yes">CHEK2</italic> LoF, and given that <italic toggle="yes">CHEK2</italic> is only a moderate risk gene, several of the tumors without LOH could also not be driven by the <italic toggle="yes">CHEK2</italic> pathogenic variants. In addition, 20 tumors from individuals with rare germline <italic toggle="yes">CHEK2</italic> MS variants of interest (<xref rid="djac196-T1" ref-type="table">Table&#160;1</xref>; <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 2</xref>, available online) were analyzed. Most of these variants except for p.Ile157Thr and p.Arg117Gly are currently classified as variants of unknown significance, and tumor sequencing showed that most retained heterozygosity with only 2 showing loss of the WT allele and 2 showing loss of the variant allele. In particular, all 3 carriers of the known pathogenic, but reduced penetrance, variant <italic toggle="yes">CHEK2</italic> p.Ile157Thr retained heterozygosity, and in the 2 tumors that were tested, neither were found to have promoter methylation.</p></sec><sec><title>Tumor sequencing in individuals with germline variants in candidate HBC genes</title><p>Tumor sequencing was performed on 57 BCs (<xref rid="djac196-T2" ref-type="table">Table&#160;2</xref>) carrying LoF (n&#8201;=&#8201;45) or rare MS (n&#8201;=&#8201;16) variants in 11 genes that have been the subject of debate in the literature (<italic toggle="yes">FANCM</italic>, <italic toggle="yes">RAD50</italic>, <italic toggle="yes">RAD51B</italic>, and <italic toggle="yes">XRCC2</italic>) or were shortlisted from the BEACCON study (<italic toggle="yes">BLM</italic>, <italic toggle="yes">CDK9</italic>, <italic toggle="yes">CTH</italic>, <italic toggle="yes">ERCC5</italic>, <italic toggle="yes">MUTYH</italic>, <italic toggle="yes">PARP2</italic>, and <italic toggle="yes">WRN</italic>) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 1</xref>, available online). The 4 BCs from <italic toggle="yes">RAD50</italic> LoF mutation carriers remained heterozygous, consistent with the accumulating literature that it does not predispose to BC (<xref rid="djac196-B21" ref-type="bibr">21</xref>). Literature support for a role of <italic toggle="yes">XRCC2</italic> in BC predisposition is weak but with a potential association with ER-negative cancer (<xref rid="djac196-B4" ref-type="bibr">4</xref>,<xref rid="djac196-B22" ref-type="bibr">22</xref>,<xref rid="djac196-B23" ref-type="bibr">23</xref>). Of the 2 BCs from <italic toggle="yes">XRCC2</italic> LoF variant carriers, only 1 (a TNBC) showed biallelic inactivation with both a high HRD score and mutational signature 3. For <italic toggle="yes">RAD51B</italic>, only tumors from carriers of rare MS variants were available with 2 remaining heterozygous and 2 showing loss of the variant allele.</p><table-wrap position="float" id="djac196-T2" orientation="portrait"><label>Table 2.</label><caption><p>Sequencing results of 57 tumors from individuals heterozygous for a germline LoF (n&#8201;=&#8201;43) or MS (n&#8201;=&#8201;16) variant in a candidate breast cancer predisposition gene (<italic toggle="yes">BLM</italic>, <italic toggle="yes">CDK9</italic>, <italic toggle="yes">CTH</italic>, <italic toggle="yes">ERCC5</italic>, <italic toggle="yes">FANCM</italic>, <italic toggle="yes">MUTYH</italic>, <italic toggle="yes">PARP2</italic>, <italic toggle="yes">RAD50</italic>, <italic toggle="yes">RAD51B</italic>, <italic toggle="yes">WRN</italic>, and <italic toggle="yes">PARP2</italic>)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">ID<xref rid="tblfn4" ref-type="table-fn"><sup>a</sup></xref></th><th rowspan="1" colspan="1">Germline gene</th><th rowspan="1" colspan="1">Variant</th><th rowspan="1" colspan="1">Variant type</th><th rowspan="1" colspan="1">Variant status<xref rid="tblfn5" ref-type="table-fn"><sup>b</sup></xref></th><th rowspan="1" colspan="1">Subtype</th><th rowspan="1" colspan="1">HRD</th><th rowspan="1" colspan="1">Somatic <italic toggle="yes">TP53</italic></th><th rowspan="1" colspan="1">Somatic <italic toggle="yes">PIK3CA</italic></th><th rowspan="1" colspan="1">Mutation signature 3<xref rid="tblfn6" ref-type="table-fn"><sup>c</sup></xref></th><th rowspan="1" colspan="1">Dominant signature</th><th rowspan="1" colspan="1">Hypermutated</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">2660</td><td rowspan="7" colspan="1">
<italic toggle="yes">BLM</italic>
</td><td rowspan="1" colspan="1">c.318_319insT,&#160;p.Leu107PhefsTer36</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">1471</td><td rowspan="1" colspan="1">c.768_769delCT,&#160;p.Leu258GlufsTer7</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Mutant Loss</td><td rowspan="1" colspan="1">ER+/HER2unknown</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">462</td><td rowspan="1" colspan="1">c.1624delG,&#160;p.Asp542ThrfsTer2</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Mutant Loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">3093</td><td rowspan="1" colspan="1">c.2695C&gt;T,&#160;p.Arg899Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">2287</td><td rowspan="1" colspan="1">c.2875C&gt;T,&#160;p.Arg959Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">2083</td><td rowspan="1" colspan="1">c.3210&#8201;+&#8201;2delT</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">c.3558&#8201;+&#8201;1G&gt;T</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2unknown</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">1245</td><td rowspan="4" colspan="1">
<italic toggle="yes">CDK9</italic>
</td><td rowspan="1" colspan="1">c.130delA,&#160;p.Lys44ArgfsTer4</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">2345</td><td rowspan="1" colspan="1">c.274delT,&#160;p.Tyr92IlefsTer23</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2+</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">3075</td><td rowspan="1" colspan="1">c.620_621insC,&#160;p.Ile210HisfsTer2</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">56</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">2723</td><td rowspan="1" colspan="1">c.689_690insG,&#160;p.Asn232GlnfsTer20</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2+</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">2045</td><td rowspan="10" colspan="1">
<italic toggle="yes">CTH</italic>
</td><td rowspan="1" colspan="1">c.465G&gt;A,&#160;p.Trp155Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">1322</td><td rowspan="1" colspan="1">c.465G&gt;A,&#160;p.Trp155Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2+</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">3119</td><td rowspan="1" colspan="1">c.465G&gt;A,&#160;p.Trp155Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2+</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">1865</td><td rowspan="1" colspan="1">c.1064delC,&#160;p.Thr355IlefsTer19</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">1092</td><td rowspan="1" colspan="1">c.230C&gt;T,&#160;p.Ala77Val</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">ESS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">5, 12</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">307</td><td rowspan="1" colspan="1">c.323T&gt;C,&#160;p.Ile108Thr</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">2593</td><td rowspan="1" colspan="1">c.620T&gt;C,&#160;p.Met207Thr</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">1065</td><td rowspan="1" colspan="1">c.718C&gt;G,&#160;p.Gln240Glu</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">4142</td><td rowspan="1" colspan="1">c.794G&gt;A,&#160;p.Arg265Gln</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">3197</td><td rowspan="1" colspan="1">c.1124G&gt;A,&#160;p.Arg375Gln</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">1, 12</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">2260</td><td rowspan="2" colspan="1">
<italic toggle="yes">ERCC5</italic>
</td><td rowspan="1" colspan="1">c.589delC,&#160;p.Pro198LeufsTer3</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Mutant Loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">901</td><td rowspan="1" colspan="1">c.1774_1775insAAGCA,&#160;p.Val592GlufsTer8</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Mutant Loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">83</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">1367</td><td rowspan="11" colspan="1">
<italic toggle="yes">FANCM</italic>
</td><td rowspan="1" colspan="1">c.2267G&gt;A,&#160;p.Arg756His</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">1709</td><td rowspan="1" colspan="1">c.3589delG,&#160;p.Asp1197MetfsTer18</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Mutant Loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">3147</td><td rowspan="1" colspan="1">c.5101C&gt;T,&#160;p.Gln1701Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">3, 6</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">691</td><td rowspan="1" colspan="1">c.5791C&gt;T,&#160;p.Arg1931Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">1172</td><td rowspan="1" colspan="1">c.5791C&gt;T,&#160;p.Arg1931Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2+</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">2771</td><td rowspan="1" colspan="1">c.5791C&gt;T,&#160;p.Arg1931Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT Loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">1, 26</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">1127</td><td rowspan="1" colspan="1">c.163G&gt;A,&#160;p.Asp55Asn</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Mutant Loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">51</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">2094</td><td rowspan="1" colspan="1">c.2267G&gt;A,&#160;p.Arg756His</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">1, 3</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">1879</td><td rowspan="1" colspan="1">c.2267G&gt;A,&#160;p.Arg756His</td><td rowspan="1" colspan="1">MS cpd</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">1, 19</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">1222</td><td rowspan="1" colspan="1">c.3998A&gt;C,&#160;p.Gln1333Pro</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">WT Loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">901</td><td rowspan="1" colspan="1">c.5108A&gt;G,&#160;p.His1703Arg</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">83</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">2743</td><td rowspan="3" colspan="1">
<italic toggle="yes">MUTYH</italic>
</td><td rowspan="1" colspan="1">c.925-2A&gt;G</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">2727<sup>&#8225;</sup></td><td rowspan="1" colspan="1">c.925-2A&gt;G</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">1253</td><td rowspan="1" colspan="1">c.384G&gt;A,&#160;p.Trp128Ter</td><td rowspan="1" colspan="1">Biallelic LoF</td><td rowspan="1" colspan="1">Germline homozygous</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">1474</td><td rowspan="5" colspan="1">
<italic toggle="yes">PARP2</italic>
</td><td rowspan="1" colspan="1">c.979_980insTT,&#160;p.Ser328CysfsTer8</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Mutant Loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">67</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">2294</td><td rowspan="1" colspan="1">c.985_986insA,&#160;p.Ile331AsnfsTer11</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER-/HER2+</td><td rowspan="1" colspan="1">81</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">333</td><td rowspan="1" colspan="1">c.1109_1110insT,&#160;p.Leu372ProfsTer2</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Mutant Loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">1185</td><td rowspan="1" colspan="1">c.1304delG,&#160;p.Val436TrpfsTer4</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER-/HER2+</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">1327</td><td rowspan="1" colspan="1">c.965G&gt;A,&#160;p.Arg322Gln</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">WT Loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">2883</td><td rowspan="4" colspan="1">
<italic toggle="yes">RAD50</italic>
</td><td rowspan="1" colspan="1">c.1291_1297delGAGATAA,&#160;p.Asp434LysfsTer7</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">2193</td><td rowspan="1" colspan="1">c.1958C&gt;A,&#160;p.Ser653Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">2251</td><td rowspan="1" colspan="1">c.2467C&gt;T,&#160;p.Arg823Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">3, 5</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">1031</td><td rowspan="1" colspan="1">c.3207delA,&#160;p.Asn1070IlefsTer6</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2+</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">2923</td><td rowspan="4" colspan="1">
<italic toggle="yes">RAD51B</italic>
</td><td rowspan="1" colspan="1">c.103C&gt;T,&#160;p.Pro35Ser</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">1932</td><td rowspan="1" colspan="1">c.277G&gt;A,&#160;p.Ala93Thr</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">1795</td><td rowspan="1" colspan="1">c.436G&gt;A,&#160;p.Ala146Thr</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Mutant Loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">3024</td><td rowspan="1" colspan="1">c.553T&gt;G,&#160;p.Cys185Gly</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Mutant Loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">3054</td><td rowspan="7" colspan="1">
<italic toggle="yes">WRN</italic>
</td><td rowspan="1" colspan="1">c.171C&gt;A,&#160;p.Tyr57Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">2963</td><td rowspan="1" colspan="1">c.944_948delTAAAC,&#160;p.Leu315PhefsTer5</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Weak</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">1115</td><td rowspan="1" colspan="1">c.3961C&gt;T,&#160;p.Arg1321Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">5, 6</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">1847</td><td rowspan="1" colspan="1">c.4216C&gt;T,&#160;p.Arg1406Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT Loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">53</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">DNT</td></tr><tr><td rowspan="1" colspan="1">2562</td><td rowspan="1" colspan="1">c.4216C&gt;T,&#160;p.Arg1406Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">3, 11</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">3093</td><td rowspan="1" colspan="1">c.4216C&gt;T,&#160;p.Arg1406Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT Loss</td><td rowspan="1" colspan="1">ER+/HER2-</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td><td rowspan="1" colspan="1">na</td></tr><tr><td rowspan="1" colspan="1">1349</td><td rowspan="1" colspan="1">c.4216C&gt;T,&#160;p.Arg1406Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">863</td><td rowspan="2" colspan="1">
<italic toggle="yes">XRCC2</italic>
</td><td rowspan="1" colspan="1">c.39&#8201;+&#8201;1G&gt;A</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">Het</td><td rowspan="1" colspan="1">ER-/HER2+</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Failed</td></tr><tr><td rowspan="1" colspan="1">3062</td><td rowspan="1" colspan="1">c.794T&gt;A,&#160;p.Leu265Ter</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">WT Loss</td><td rowspan="1" colspan="1">TN</td><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1">LoF</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">Strong</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">DNT</td></tr></tbody></table><table-wrap-foot><fn id="tblfn4"><label>a</label><p>Subject 2727 also carried a germline ATM variant that had biallelic loss in tumor. Subject 3054 carried a germline <italic toggle="yes">RAD51C</italic> that had biallelic loss in tumor. Subject 3093 carried variants of interest in <italic toggle="yes">BLM</italic> and <italic toggle="yes">WRN</italic>. Subject 901 carried variants in both <italic toggle="yes">ERCC5</italic> and <italic toggle="yes">FANCM</italic>. &#8220;&#8212;&#8221; signifies feature not present. BC = breast cancer; DNT = did not test; na = not available; ER+ = estrogen receptor&#8211;positive breast cancer; HER2- = HER2 negative; HER2+ = HER2 positive; HRD = homologous recombination deficiency score; LoF = loss of function; MS = missense; TN = triple-negative; WT = wild type.</p></fn><fn id="tblfn5"><label>b</label><p>WT loss, somatic loss of the wild-type allele; Mutant loss, somatic loss of the allele carrying the known germline variant, Het, heterozygous. Case 425 showed loss of heterozygosity across the gene regions but unable to determine which allele had been lost.</p></fn><fn id="tblfn6"><label>c</label><p>Proportion of mutational signature 3 (COSMIC v2, assessed on whole-exome sequenced tumors only) above 25% is classified as &#8220;strong,&#8221; below 25% as &#8220;weak.&#8221;</p></fn></table-wrap-foot></table-wrap><p>LoF mutations in <italic toggle="yes">FANCM</italic> have previously been reported to be associated with a small increase in BC risk (<xref rid="djac196-B24" ref-type="bibr">24-26</xref>), but 4 of 6 tumors from individuals with <italic toggle="yes">FANCM</italic> LoF variants remained heterozygous with only 1 having lost the WT allele and did not show a high HRD score. Similarly, there was no consistent loss of the WT allele in tumors associated with germline <italic toggle="yes">FANCM</italic> MS variants (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 3</xref>, available online). <italic toggle="yes">BLM</italic> has previously been implicated in BC predisposition (<xref rid="djac196-B27" ref-type="bibr">27-29</xref>) and in the BEACCON data (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 1</xref>, available online), but 5 of the BCs with LoF variants remained heterozygous with no evidence of promoter hypermethylation, whereas 2 BCs lost the LoF allele.</p><p>For the candidate genes, loss of the WT allele was not observed for the majority. The BCs carrying LoF or MS variants in the candidate genes <italic toggle="yes">CDK9</italic> and <italic toggle="yes">CTH</italic> (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 4</xref>, available online) remained heterozygous although promoter methylation assessment was not successful for these genes. Of the 4 <italic toggle="yes">PARP2</italic> BCs with LoF mutations, 2 showed loss of the LoF allele with the other 2 remaining heterozygous. The 2 <italic toggle="yes">ERCC5</italic> BCs showed loss of the LoF allele. In contrast, the <italic toggle="yes">WRN</italic> gene, which was found to have a statistcally significant association with ER-positive BC in the BEACCON study (unadjusted <italic toggle="yes">P</italic>&#8201;=&#8201;.003), showed loss of the WT allele in 2 of 6 ER-positive cases. A <italic toggle="yes">WRN</italic>-heterozygous BC also carried an <italic toggle="yes">ATM</italic> germline variant that had experienced biallelic loss, suggesting that the <italic toggle="yes">ATM</italic> variant was instead responsible for the tumor. Overall, evidence of loss of the WT allele was rare among candidate genes despite evidence in case-control frequencies.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The frequent observation of loss of the WT allele in BCs carrying germline pathogenic mutations in <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> supports the model of biallelic inactivation being required for BC predisposition, at least in some high penetrance genes. Recent studies indicate that biallelic inactivation is also common in BCs carrying pathogenic mutations in <italic toggle="yes">PALB2</italic> (<xref rid="djac196-B12" ref-type="bibr">12</xref>,<xref rid="djac196-B30" ref-type="bibr">30</xref>,<xref rid="djac196-B31" ref-type="bibr">31</xref>) and <italic toggle="yes">ATM</italic> (<xref rid="djac196-B13" ref-type="bibr">13</xref>) and has been used as a biomarker to support the role of <italic toggle="yes">RAD51C</italic> (<xref rid="djac196-B11" ref-type="bibr">11</xref>) as a TNBC predisposition gene. These examples suggest tumor sequencing can provide a useful orthogonal approach to validate new BC genes and rare MS variants in known genes.</p><p>In this study, tumor sequencing demonstrated that TN tumors from <italic toggle="yes">BARD1</italic> LoF mutation carriers frequently exhibit biallelic inactivation consistent with data from case-control studies (<xref rid="djac196-B3" ref-type="bibr">3-5</xref>) that indicate that <italic toggle="yes">BARD1</italic> pathogenic variants are associated with predisposition to TNBC. Recent case-control studies have also provided support for the role of <italic toggle="yes">RAD51D</italic> in TNBC predisposition (<xref rid="djac196-B4" ref-type="bibr">4</xref>). Although 1 of 2 LoF BCs studied here showed loss of the WT allele, the rarity of its variants precluded any confident conclusion to be drawn. <italic toggle="yes">RAD51D</italic> MS variants as a group showed an excess in the BEACCON case-control analysis, but most of the tumors from rare MS variant carriers showed no evidence of a second hit, and the 2 cases with loss of the WT allele had low HRD scores suggesting they are benign variants.</p><p>The role of <italic toggle="yes">BRIP1</italic> in BC predisposition is debated with most, but not all, published case-control studies failing to identify a statistically significant excess of LoF mutations in cases (<xref rid="djac196-B4" ref-type="bibr">4</xref>,<xref rid="djac196-B5" ref-type="bibr">5</xref>). Tumor sequencing did not find evidence to support a role for <italic toggle="yes">BRIP1</italic> in BC predisposition with most BCs remaining heterozygous and, importantly, an equivalent number of cases losing the WT and LoF alleles. Previous tumor sequencing studies on <italic toggle="yes">BRIP1</italic> BCs are limited, but our findings are consistent with a previous report on 3 <italic toggle="yes">BRIP1</italic> BC where only 1 was found to have biallelic inactivation (<xref rid="djac196-B10" ref-type="bibr">10</xref>). Overall, our results for <italic toggle="yes">BARD1</italic>, <italic toggle="yes">RAD51D</italic>, and <italic toggle="yes">BRIP1</italic> are consistent with the findings of 2 recent large case-control studies cited previously (<xref rid="djac196-B4" ref-type="bibr">4</xref>,<xref rid="djac196-B5" ref-type="bibr">5</xref>) where <italic toggle="yes">BARD1</italic> and <italic toggle="yes">RAD51D</italic> are associated with BC, specifically TNBC, whereas no causative link was identified for <italic toggle="yes">BRIP1</italic>.</p><p>Based on the data for <italic toggle="yes">BARD1</italic> and the other previously studied BC predisposing genes <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">PALB2</italic>, and <italic toggle="yes">ATM</italic>, it might be extrapolated that biallelic inactivation is a typical feature for all BC predisposition genes. However, the data for <italic toggle="yes">CHEK2</italic>, which has highly robust case-control evidence supporting its role as a moderate penetrance BC gene, suggest that this is not true in all cases. Of the 17 BCs with germline <italic toggle="yes">CHEK2</italic> LoF mutations, only 6 showed loss of the WT allele, and the majority (53%) showed no evidence of biallelic loss. The established low penetrance <italic toggle="yes">CHEK2</italic> variant p.Ile157Thr was also not detected with WT allele loss. This is consistent with previous studies that found that LOH across <italic toggle="yes">CHEK2</italic> in BCs from LoF mutation carriers was infrequent (32 of 93, 34%) (<xref rid="djac196-B32" ref-type="bibr">32-37</xref>) and occurs at a similar rate in sporadic BCs (40%, n&#8201;=&#8201;560) (<xref rid="djac196-B38" ref-type="bibr">38</xref>). A recent sequencing-based study reported that 13 of 16 (81%) BC from <italic toggle="yes">CHEK2</italic> LoF carriers had biallelic inactivation (<xref rid="djac196-B32" ref-type="bibr">32</xref>), however, only 5 of the 8 (63%) <italic toggle="yes">CHEK2</italic>-null tumors were of ER-positive and HER2-negative ductal histological subtype that are known to be associated with <italic toggle="yes">CHEK2</italic> predisposition. Our data based on 17 LoF and 20 MS <italic toggle="yes">CHEK2</italic> variant-carrying tumors suggested that although <italic toggle="yes">CHEK2</italic> displayed a selective predisposition to ER-positive ductal BC, there was no consistent biallelic inactivation, and the BCs had low mutational burden and were not consistently associated with a characteristic mutational signature or somatic driver mutations. These data suggest that the effect of pathogenic variants in <italic toggle="yes">CHEK2</italic> is possibly mediated by haploinsufficiency (<xref rid="djac196-B39" ref-type="bibr">39</xref>), which has implications for the reliability of using biallelic inactivation as an indicator of disease association.</p><p>Candidate genes analyzed in this study were identified in the BEACCON case-control and included <italic toggle="yes">BLM</italic>, <italic toggle="yes">PARP2</italic>, and <italic toggle="yes">WRN</italic>, which showed statistically significant association with BC with odds ratios of 2.5, 5.0, and 2.0, respectively, whereas other candidate genes <italic toggle="yes">CDK9</italic>, <italic toggle="yes">CTH</italic>, and <italic toggle="yes">XRCC2</italic> also showed relatively high odds ratios despite the small number of cases. The BEACCON study included more than 11&#8202;500 subjects with enrichment for high-risk familial cases, however, LoF variants in candidate genes were still too rare to confidently assert a genuine association with BC predisposition. Inclusion of tumor sequencing from 57 cases did not provide definitive evidence for their roles in BC predisposition: 1 of 2 <italic toggle="yes">XRCC2</italic> and 2 of 7 <italic toggle="yes">WRN</italic> BCs were among the minority that showed loss of the WT allele. Despite multiple studies reporting an association with <italic toggle="yes">BLM</italic>, no instance of biallelic inactivation has been found in <italic toggle="yes">BLM</italic>-carrying tumors to date<italic toggle="yes">,</italic> including our study of 7 tumors and the previous evaluation of 22 cases across 3 studies (<xref rid="djac196-B28" ref-type="bibr">28</xref>,<xref rid="djac196-B34" ref-type="bibr">34</xref>,<xref rid="djac196-B40" ref-type="bibr">40</xref>). Despite early studies and inclusion of <italic toggle="yes">RAD50</italic> in many HBC gene panels (<xref rid="djac196-B41" ref-type="bibr">41</xref>,<xref rid="djac196-B42" ref-type="bibr">42</xref>), recent large studies have demonstrated that it is not a BC predisposition gene (<xref rid="djac196-B4" ref-type="bibr">4</xref>,<xref rid="djac196-B5" ref-type="bibr">5</xref>), consistent with the findings in the 4 <italic toggle="yes">RAD50</italic> tumors analyzed here, which all remained heterozygous.</p><p>Findings from this study have demonstrated that tumor sequencing is useful in validating BC predisposing genes that operate in carcinogenesis through a mechanism of biallelic inactivation, such as <italic toggle="yes">BARD1.</italic> However, based on the evidence from <italic toggle="yes">CHEK2</italic>-associated tumors, the absence of biallelic inactivation does not appear to preclude a role in BC predisposition. It is interesting to note that most of the established HBC genes that have been shown to undergo frequent biallelic inactivation in breast tumors, such as <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">PALB2</italic>, and <italic toggle="yes">RAD51C</italic>, are highly penetrant and/or predispose selectively to TNBC, currently the sole exception being <italic toggle="yes">ATM</italic>, which is a moderate penetrance and ER-positive BC-associated gene. Interestingly, similar to <italic toggle="yes">CHEK2</italic>, the lower penetrance <italic toggle="yes">BRCA2</italic> variant p.Lys3326Ter does not appear to require biallelic activation. A recent study of 26 <italic toggle="yes">BRCA2</italic> p.Lys3326Ter-associated breast tumors found no instance of LOH (<xref rid="djac196-B43" ref-type="bibr">43</xref>).</p><p>Despite the ready availability of archival formalin-fixed, paraffin-embedded tumor blocks from BEACCON study participants, the main limitation to this study, was the small sample size for rare genes. In addition, the quality of formalin-fixed, paraffin-embedded tumor samples may cause potential errors in the determination of LOH. Tumor purity, especially in tumors that have high levels of infiltrating lymphocytes, may also introduce further complexity to the interpretation of allele frequency and copy number status, as addressed in the methods. Lastly, because of the greater requirements in terms of tumor DNA quality and quantity, methylation sequencing was not able to be carried out for all samples, therefore promoter hypermethylation cannot be ruled out for those samples, although in this study, no such instance was found.</p><p>In summary, this study demonstrates the utility of inclusion of tumor sequencing in HBC gene discovery and validation, but the absence of consistent biallelic inactivation in <italic toggle="yes">CHEK2</italic> suggests this approach might not be reliable for lower penetrance genes.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>djac196_Supplementary_Data</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="djac196_supplementary_data.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><sec><title>Funding</title><p>This work was supported by the National Breast Cancer Foundation (IF-15-004, IGC and PAJ), Cancer Australia/National Breast Cancer Foundation (PdCCRS_1107870, IGC and PAJ), Cancer Australia/National Breast Cancer Foundation (PdCCRS_1188547, IGC and PAJ), the Victorian Cancer Agency (Tumor Stream Grant, PAJ), the National Health and Medical Research Council of Australia (GNT1023698, PAJ; GNT1041975, IGC) and Cancer Australia (PdCCRS_1188547, IGC, PAJ, and EKS). EKS is supported by the National Health and Medical Research Council GNT114749, the National Breast Cancer Foundation IIRS-20-025 and Cancer Council Victoria Grants-in-Aid. NL is supported by Cancer Council Victoria.</p></sec><sec><title>Notes</title><p>
<bold>Role of the funder:</bold> The funding sources did not participate in the design and conduct of the study, the collection, analysis, and interpretation of the data, the preparation and writing of the manuscript, and the decision to submit the manuscript for publication.</p><p>
<bold>Disclosures</bold>: The authors declare that there are no competing interests.</p><p>
<bold>Author contributions:</bold> Conceptualization: IGC, PAJ. Data curation: BWXL, NL, SMR, MZ. Formal analysis: BWXL, IGC, PAJ. Funding acquisition: IGC, PAJ. Investigation: BWXL, NL, SM, SM, MZ, SMR, JH, TW, MF, AJEL, LD, RJS, EKS, PAJ, IGC. Methodology: BWXL, NL, MZ, PAJ, IGC. Resources: IGC, PAJ, RJS. Supervision: IGC, PAJ. Visualization: BWXL, NL, MZ. Writing&#8212;original draft: BWXL, IGC, PAJ, EKS. Writing&#8212;review &amp; editing: BWXL, NL, SM, MZ, LD, EKS, RJS, PAJ, IGC.</p><p>
<bold>Acknowledgements:</bold> The authors thank all the participants of the Variants in Practice and Lifepool studies for donating their DNA samples and clinical information. We also thank Norah Grewal, the Variants in Practice study site principal investigators Geoffrey Lindeman, Marion Harris, Lucinda Salmon, Ingrid Winship, and Yoland Antill and the staff at the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Monash Health, Cabrini Health and Barwon Health Familial Cancer Centres, and the Austin and Tasmanian Clinical Genetics Services, who enrolled participants and provided clinical data. We thank the following staff from Peter MacCallum Cancer Centre; Kaushalya Amarasinghe, Niko Thio, and Richard Lupat from Bioinformatics core facility for helping with the bioinformatic analysis and Steven Macaskill from Pathology Lab for Sanger sequencing services.</p><p>
<bold>Prior presentations:</bold> Part of this study was presented at BRCA Symposium 2021, Montreal, Canada and Familial Aspects of Cancer Conference 2021, Melbourne, Australia.</p></sec><sec sec-type="data-availability"><title>Data availability</title><p>All sequencing data has been deposited to the European Genome-phenome Archive under accession numbers Study: EGAS00001006532 and Dataset: EGAD00001009299. Standard R codes were used. Code requests should be addressed to Prof. Ian Campbell.</p></sec><ref-list id="ref1"><title>References</title><ref id="djac196-B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Narod</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Foulkes</surname><given-names>WD.</given-names></string-name></person-group><article-title>BRCA1 and BRCA2: 1994 and beyond</article-title>. <source>Nat Rev Cancer</source>. <year>2004</year>;<volume>4</volume>(<issue>9</issue>):<fpage>665</fpage>-<lpage>676</lpage>.<pub-id pub-id-type="pmid">15343273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc1431</pub-id></mixed-citation></ref><ref id="djac196-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Antoniou</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Casadei</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Heikkinen</surname><given-names>T</given-names></string-name></person-group>, <etal>et al</etal><article-title>Breast-cancer risk in families with mutations in PALB2</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>371</volume>(<issue>6</issue>):<fpage>497</fpage>-<lpage>506</lpage>.<pub-id pub-id-type="pmid">25099575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1400382</pub-id><pub-id pub-id-type="pmcid">PMC4157599</pub-id></mixed-citation></ref><ref id="djac196-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>BWX</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>ER</given-names></string-name></person-group>, <etal>et al</etal><article-title>Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study</article-title>. <source>NPJ Breast Cancer</source>. <year>2021</year>;<volume>7</volume>(<issue>1</issue>):<fpage>76</fpage>.<pub-id pub-id-type="pmid">34117267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41523-021-00279-9</pub-id><pub-id pub-id-type="pmcid">PMC8196173</pub-id></mixed-citation></ref><ref id="djac196-B4"><label>4</label><mixed-citation publication-type="journal"><collab>Breast Cancer Association Consortium</collab>. <article-title>Breast cancer risk genes&#8212;association analysis in more than 113,000 women</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>384</volume>(<issue>5</issue>):<fpage>428</fpage>-<lpage>439</lpage>.<pub-id pub-id-type="pmid">33471991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1913948</pub-id><pub-id pub-id-type="pmcid">PMC7611105</pub-id></mixed-citation></ref><ref id="djac196-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hart</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Gnanaolivu</surname><given-names>R</given-names></string-name></person-group>, <etal>et al</etal><article-title>A population-based study of genes previously implicated in breast cancer</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>384</volume>(<issue>5</issue>):<fpage>440</fpage>-<lpage>451</lpage>.<pub-id pub-id-type="pmid">33471974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2005936</pub-id><pub-id pub-id-type="pmcid">PMC8127622</pub-id></mixed-citation></ref><ref id="djac196-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maxwell</surname><given-names>KN</given-names></string-name>, <string-name name-style="western"><surname>Wubbenhorst</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wenz</surname><given-names>BM</given-names></string-name></person-group>, <etal>et al</etal><article-title>BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers</article-title>. <source>Nat Commun</source>. <year>2017</year>;<volume>8</volume>(<issue>1</issue>):<fpage>319</fpage>.<pub-id pub-id-type="pmid">28831036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-017-00388-9</pub-id><pub-id pub-id-type="pmcid">PMC5567274</pub-id></mixed-citation></ref><ref id="djac196-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sokol</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Pavlick</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Khiabanian</surname><given-names>H</given-names></string-name></person-group>, <etal>et al</etal><article-title>Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity</article-title>. <source>J Clin Oncol Precis Oncol</source>. <year>2020</year>;<volume>4</volume>:<fpage>442</fpage>-<lpage>465</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.19.00345</pub-id><pub-id pub-id-type="pmcid">PMC7446440</pub-id><pub-id pub-id-type="pmid">32903788</pub-id></mixed-citation></ref><ref id="djac196-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tung</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Miron</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Schnitt</surname><given-names>SJ</given-names></string-name></person-group>, <etal>et al</etal><article-title>Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers</article-title>. <source>Breast Cancer Res</source>. <year>2010</year>;<volume>12</volume>(<issue>6</issue>):<fpage>R95</fpage>.<pub-id pub-id-type="pmid">21080930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/bcr2776</pub-id><pub-id pub-id-type="pmcid">PMC3046438</pub-id></mixed-citation></ref><ref id="djac196-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Osorio</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>de la Hoya</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez-Lopez</surname><given-names>R</given-names></string-name></person-group>, <etal>et al</etal><article-title>Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer</article-title>. <source>Int J Cancer</source>. <year>2002</year>;<volume>99</volume>(<issue>2</issue>):<fpage>305</fpage>-<lpage>309</lpage>.<pub-id pub-id-type="pmid">11979449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.10337</pub-id></mixed-citation></ref><ref id="djac196-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Polak</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Braunstein</surname><given-names>LZ</given-names></string-name></person-group>, <etal>et al</etal><article-title>A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer</article-title>. <source>Nat Genet</source>. <year>2017</year>;<volume>49</volume>(<issue>10</issue>):<fpage>1476</fpage>-<lpage>1486</lpage>.<pub-id pub-id-type="pmid">28825726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3934</pub-id><pub-id pub-id-type="pmcid">PMC7376751</pub-id></mixed-citation></ref><ref id="djac196-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>McInerny</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zethoven</surname><given-names>M</given-names></string-name></person-group>, <etal>et al</etal><article-title>Combined tumor sequencing and case/control analyses of RAD51C in breast cancer</article-title>. <source>J Natl Cancer Inst</source>. <year>2019</year>;111(12):<fpage>1332</fpage>-<lpage>1338</lpage>.<pub-id pub-id-type="pmid">30949688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djz045</pub-id><pub-id pub-id-type="pmcid">PMC6910168</pub-id></mixed-citation></ref><ref id="djac196-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>JEA</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Rowley</surname><given-names>SM</given-names></string-name></person-group>, <etal>et al</etal><article-title>Molecular analysis of PALB2-associated breast cancers</article-title>. <source>J Pathol</source>. <year>2018</year>;<volume>245</volume>(<issue>1</issue>):<fpage>53</fpage>-<lpage>60</lpage>.<pub-id pub-id-type="pmid">29431189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/path.5055</pub-id></mixed-citation></ref><ref id="djac196-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weigelt</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>R</given-names></string-name></person-group>, <etal>et al</etal>; for the <collab>kConFab Investigators</collab>. <article-title>The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers</article-title>. <source>J Natl Cancer Inst</source>. <year>2018</year>;<volume>110</volume>(<issue>9</issue>):<fpage>1030</fpage>-<lpage>1034</lpage>.<pub-id pub-id-type="pmid">29506079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djy028</pub-id><pub-id pub-id-type="pmcid">PMC6136925</pub-id></mixed-citation></ref><ref id="djac196-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Telli</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Timms</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Reid</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal><article-title>Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer</article-title>. <source>Clin Cancer Res</source>. <year>2016</year>;<volume>22</volume>(<issue>15</issue>):<fpage>3764</fpage>-<lpage>3773</lpage>.<pub-id pub-id-type="pmid">26957554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-15-2477</pub-id><pub-id pub-id-type="pmcid">PMC6773427</pub-id></mixed-citation></ref><ref id="djac196-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lanchbury</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Timms</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Reid</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal><article-title>3-biomarker HRD score versus individual biomarker (LOH, TAI, LST) scores in platinum treated serous ovarian cancer (SOC)</article-title>. <source>Ann Oncol</source>. <year>2016</year>;<volume>27(Suppl 6)</volume>:<fpage>vi34</fpage>.</mixed-citation></ref><ref id="djac196-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rosenthal</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>McGranahan</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Herrero</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Swanton</surname><given-names>C.</given-names></string-name></person-group><article-title>DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution</article-title>. <source>Genome Biol</source>. <year>2016</year>;<volume>17</volume>:<fpage>31</fpage>.<pub-id pub-id-type="pmid">26899170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-016-0893-4</pub-id><pub-id pub-id-type="pmcid">PMC4762164</pub-id></mixed-citation></ref><ref id="djac196-B17"><label>17</label><mixed-citation publication-type="book"><collab>R Core Team</collab>. <source>R: A Language and Environment for Statistical Computing</source>. <publisher-loc>Vienna, Austria</publisher-loc>: <publisher-name>R Foundation for Statistical Computing</publisher-name>; <year>2016</year>.</mixed-citation></ref><ref id="djac196-B18"><label>18</label><mixed-citation publication-type="journal">Thompson ER, Rowley SM, Li N, et al. <article-title>Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care</article-title>. <source>J Clin Oncol</source>. <year>2016</year>;<volume>34</volume>(<issue>13</issue>):<fpage>1455</fpage>-<lpage>1459</lpage>.<pub-id pub-id-type="pmid">26786923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2015.63.7454</pub-id></mixed-citation></ref><ref id="djac196-B19"><label>19</label><mixed-citation publication-type="journal">Rowley SM, Mascarenhas L, Devereux L, et al. <article-title>Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility</article-title>. <source>Genet Med.</source><year>2019</year>;<volume>21</volume>(<issue>4</issue>):<fpage>913</fpage>-<lpage>922</lpage>.<pub-id pub-id-type="pmid">30254378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41436-018-0277-0</pub-id></mixed-citation></ref><ref id="djac196-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weischer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bojesen</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Ellervik</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tybj&#230;rg-Hansen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nordestgaard</surname><given-names>BG.</given-names></string-name></person-group><article-title>CHEK21100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls</article-title>. <source>J Clin Oncol</source>. <year>2008</year>;<volume>26</volume>(<issue>4</issue>):<fpage>542</fpage>-<lpage>548</lpage>.<pub-id pub-id-type="pmid">18172190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2007.12.5922</pub-id></mixed-citation></ref><ref id="djac196-B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Couch</surname><given-names>FJ</given-names></string-name>, <string-name name-style="western"><surname>Shimelis</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>C</given-names></string-name></person-group>, <etal>et al</etal><article-title>Associations between cancer predisposition testing panel genes and breast cancer</article-title>. <source>JAMA Oncol</source>. <year>2017</year>;<volume>3</volume>(<issue>9</issue>):<fpage>1190</fpage>-<lpage>1196</lpage>.<pub-id pub-id-type="pmid">28418444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2017.0424</pub-id><pub-id pub-id-type="pmcid">PMC5599323</pub-id></mixed-citation></ref><ref id="djac196-B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hilbers</surname><given-names>FS</given-names></string-name>, <string-name name-style="western"><surname>Wijnen</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Hoogerbrugge</surname><given-names>N</given-names></string-name></person-group>, <etal>et al</etal><article-title>Rare variants in XRCC2 as breast cancer susceptibility alleles</article-title>. <source>J Med Genet</source>. <year>2012</year>;<volume>49</volume>(<issue>10</issue>):<fpage>618</fpage>-<lpage>620</lpage>.<pub-id pub-id-type="pmid">23054243</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmedgenet-2012-101191</pub-id></mixed-citation></ref><ref id="djac196-B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Park</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Lesueur</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Nguyen-Dumont</surname><given-names>T</given-names></string-name></person-group>, <etal>et al</etal>; for the <collab>Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer</collab>. <article-title>Rare mutations in XRCC2 increase the risk of breast cancer</article-title>. <source>Am J Hum Genet</source>. <year>2012</year>;<volume>90</volume>(<issue>4</issue>):<fpage>734</fpage>-<lpage>739</lpage>.<pub-id pub-id-type="pmid">22464251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2012.02.027</pub-id><pub-id pub-id-type="pmcid">PMC3322233</pub-id></mixed-citation></ref><ref id="djac196-B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Figlioli</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bogliolo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Catucci</surname><given-names>I</given-names></string-name></person-group>, <etal>et al</etal>; for <collab>kConFab</collab>. <article-title>The FANCM:p.Arg658 truncating variant is associated with risk of triple-negative breast cancer</article-title>. <source>NPJ Breast Cancer</source>. <year>2019</year>;<volume>5</volume>(<issue>1</issue>):<fpage>38</fpage>.<pub-id pub-id-type="pmid">31700994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41523-019-0127-5</pub-id><pub-id pub-id-type="pmcid">PMC6825205</pub-id></mixed-citation></ref><ref id="djac196-B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kiiski</surname><given-names>JI</given-names></string-name>, <string-name name-style="western"><surname>Pelttari</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>S</given-names></string-name></person-group>, <etal>et al</etal><article-title>Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2014</year>;<volume>111</volume>(<issue>42</issue>):<fpage>15172</fpage>-<lpage>15177</lpage>.<pub-id pub-id-type="pmid">25288723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1407909111</pub-id><pub-id pub-id-type="pmcid">PMC4210278</pub-id></mixed-citation></ref><ref id="djac196-B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Neidhardt</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hauke</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ramser</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal><article-title>Association between loss-of-function mutations within the FANCM gene and early-onset familial breast cancer</article-title>. <source>JAMA Oncol</source>. <year>2017</year>;<volume>3</volume>(<issue>9</issue>):<fpage>1245</fpage>-<lpage>1248</lpage>.<pub-id pub-id-type="pmid">28033443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2016.5592</pub-id><pub-id pub-id-type="pmcid">PMC5824291</pub-id></mixed-citation></ref><ref id="djac196-B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Prokofyeva</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bogdanova</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Dubrowinskaja</surname><given-names>N</given-names></string-name></person-group>, <etal>et al</etal><article-title>Nonsense mutation p.Q548X in BLM, the gene mutated in Bloom&#8217;s syndrome, is associated with breast cancer in Slavic populations</article-title>. <source>Breast Cancer Res Treat</source>. <year>2013</year>;<volume>137</volume>(<issue>2</issue>):<fpage>533</fpage>-<lpage>539</lpage>.<pub-id pub-id-type="pmid">23225144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-012-2357-1</pub-id></mixed-citation></ref><ref id="djac196-B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sokolenko</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Iyevleva</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Preobrazhenskaya</surname><given-names>EV</given-names></string-name></person-group>, <etal>et al</etal><article-title>High prevalence and breast cancer predisposing role of the BLM c.1642 C&gt;T (Q548X) mutation in Russia</article-title>. <source>Int J Cancer</source>. <year>2012</year>;<volume>130</volume>(<issue>12</issue>):<fpage>2867</fpage>-<lpage>2873</lpage>.<pub-id pub-id-type="pmid">21815139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.26342</pub-id></mixed-citation></ref><ref id="djac196-B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thompson</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Doyle</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Ryland</surname><given-names>GL</given-names></string-name></person-group>, <etal>et al</etal>; for <collab>kConFab</collab>. <article-title>Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles</article-title>. <source>PLoS Genet</source>. <year>2012</year>;<volume>8</volume>(<issue>9</issue>):<fpage>e1002894</fpage>.<pub-id pub-id-type="pmid">23028338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1002894</pub-id><pub-id pub-id-type="pmcid">PMC3459953</pub-id></mixed-citation></ref><ref id="djac196-B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Geyer</surname><given-names>FC</given-names></string-name>, <string-name name-style="western"><surname>Blecua</surname><given-names>P</given-names></string-name></person-group>, <etal>et al</etal>; for <collab>kConFab Investigators</collab>. <article-title>Homologous recombination DNA repair defects in PALB2-associated breast cancers</article-title>. <source>NPJ Breast Cancer</source>. <year>2019</year>;<volume>5</volume>(<issue>1</issue>):<fpage>23</fpage>.<pub-id pub-id-type="pmid">31428676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41523-019-0115-9</pub-id><pub-id pub-id-type="pmcid">PMC6687719</pub-id></mixed-citation></ref><ref id="djac196-B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ng</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Ahmad Zabidi</surname><given-names>MM</given-names></string-name></person-group>, <etal>et al</etal><article-title>Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses</article-title>. <source>NPJ Breast Cancer</source>. <year>2021</year>;<volume>7</volume>(<issue>1</issue>):<fpage>46</fpage>.<pub-id pub-id-type="pmid">33893315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41523-021-00254-4</pub-id><pub-id pub-id-type="pmcid">PMC8065101</pub-id></mixed-citation></ref><ref id="djac196-B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mandelker</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pei</surname><given-names>X</given-names></string-name></person-group>, <etal>et al</etal><article-title>The landscape of somatic genetic alterations in breast cancers from <italic toggle="yes">CHEK2</italic> germline mutation carriers</article-title>. <source>JNCI Cancer Spectr</source>. <year>2019</year>;<volume>3</volume>(<issue>2</issue>):<fpage>pkz027</fpage>.<pub-id pub-id-type="pmid">31360903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jncics/pkz027</pub-id><pub-id pub-id-type="pmcid">PMC6649818</pub-id></mixed-citation></ref><ref id="djac196-B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Massink</surname><given-names>MPG</given-names></string-name>, <string-name name-style="western"><surname>Kooi</surname><given-names>IE</given-names></string-name>, <string-name name-style="western"><surname>Martens</surname><given-names>JWM</given-names></string-name>, <string-name name-style="western"><surname>Waisfisz</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Meijers-Heijboer</surname><given-names>H.</given-names></string-name></person-group><article-title>Genomic profiling of CHEK2*1100delC-mutated breast carcinomas</article-title>. <source>BMC Cancer</source>. <year>2015</year>;<volume>15</volume>:<fpage>877</fpage>-<pub-id pub-id-type="pmid">26553136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-015-1880-y</pub-id><pub-id pub-id-type="pmcid">PMC4640207</pub-id></mixed-citation></ref><ref id="djac196-B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Suspitsin</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Yanus</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Sokolenko</surname><given-names>AP</given-names></string-name></person-group>, <etal>et al</etal><article-title>Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele</article-title>. <source>Med Oncol</source>. <year>2014</year>;<volume>31</volume>(<issue>2</issue>):<fpage>828</fpage>.<pub-id pub-id-type="pmid">24415413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12032-013-0828-9</pub-id></mixed-citation></ref><ref id="djac196-B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Muranen</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Greco</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fagerholm</surname><given-names>R</given-names></string-name></person-group>, <etal>et al</etal><article-title>Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications</article-title>. <source>Breast Cancer Res</source>. <year>2011</year>;<volume>13</volume>(<issue>5</issue>):<fpage>R90</fpage>.<pub-id pub-id-type="pmid">21542898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/bcr3015</pub-id><pub-id pub-id-type="pmcid">PMC3262202</pub-id></mixed-citation></ref><ref id="djac196-B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oldenburg</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Kroeze-Jansema</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kraan</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal><article-title>The CHEK21100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families</article-title>. <source>Cancer Res</source>. <year>2003</year>;<volume>63</volume>(<issue>23</issue>):<fpage>8153</fpage>-<lpage>8157</lpage>.<pub-id pub-id-type="pmid">14678969</pub-id></mixed-citation></ref><ref id="djac196-B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sodha</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bullock</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname><given-names>R</given-names></string-name></person-group>, <etal>et al</etal><article-title>CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours</article-title>. <source>Br J Cancer</source>. <year>2002</year>;<volume>87</volume>(<issue>12</issue>):<fpage>1445</fpage>-<lpage>1448</lpage>.<pub-id pub-id-type="pmid">12454775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bjc.6600637</pub-id><pub-id pub-id-type="pmcid">PMC2376278</pub-id></mixed-citation></ref><ref id="djac196-B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nik-Zainal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Davies</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Staaf</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal><article-title>Landscape of somatic mutations in 560 breast cancer whole-genome sequences</article-title>. <source>Nature</source>. <year>2016</year>;<volume>534</volume>(<issue>7605</issue>):<fpage>47</fpage>-<lpage>54</lpage>.<pub-id pub-id-type="pmid">27135926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature17676</pub-id><pub-id pub-id-type="pmcid">PMC4910866</pub-id></mixed-citation></ref><ref id="djac196-B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Teugels</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>De Brakeleer</surname><given-names>S.</given-names></string-name></person-group><article-title>An alternative model for (breast) cancer predisposition</article-title>. <source>NPJ Breast Cancer</source>. <year>2017</year>;<volume>3</volume>(<issue>1</issue>):<fpage>13</fpage>.<pub-id pub-id-type="pmid">28649653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41523-017-0017-7</pub-id><pub-id pub-id-type="pmcid">PMC5460113</pub-id></mixed-citation></ref><ref id="djac196-B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Klu&#378;niak</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Woko&#322;orczyk</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rusak</surname><given-names>B</given-names></string-name></person-group>, <etal>et al</etal><article-title>Inherited variants in BLM and the risk and clinical characteristics of breast cancer</article-title>. <source>Cancers (Basel)</source>. <year>2019</year>;<volume>11</volume>(<issue>10</issue>):<fpage>1548</fpage>.<pub-id pub-id-type="pmid">31614901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers11101548</pub-id><pub-id pub-id-type="pmcid">PMC6826355</pub-id></mixed-citation></ref><ref id="djac196-B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Heikkinen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Rapakko</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Karppinen</surname><given-names>S-M</given-names></string-name></person-group>, <etal>et al</etal><article-title>RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability</article-title>. <source>Carcinogenesis</source>. <year>2006</year>;<volume>27</volume>(<issue>8</issue>):<fpage>1593</fpage>-<lpage>1599</lpage>.<pub-id pub-id-type="pmid">16474176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/carcin/bgi360</pub-id><pub-id pub-id-type="pmcid">PMC3006189</pub-id></mixed-citation></ref><ref id="djac196-B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tommiska</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Seal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Renwick</surname><given-names>A</given-names></string-name></person-group>, <etal>et al</etal><article-title>Evaluation of RAD50 in familial breast cancer predisposition</article-title>. <source>Int J Cancer</source>. <year>2006</year>;<volume>118</volume>(<issue>11</issue>):<fpage>2911</fpage>-<lpage>2916</lpage>.<pub-id pub-id-type="pmid">16385572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.21738</pub-id></mixed-citation></ref><ref id="djac196-B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Butz</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Papp</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bozsik</surname><given-names>A</given-names></string-name></person-group>, <etal>et al</etal><article-title>Application of multilayer evidence for annotation of c-terminal BRCA2 variants</article-title>. <source>Cancers (Basel)</source>. <year>2021</year>;<volume>13</volume>(<issue>4</issue>):<fpage>881</fpage>.<pub-id pub-id-type="pmid">33672545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13040881</pub-id><pub-id pub-id-type="pmcid">PMC7923782</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>